Randomized, Open-Label 2x2 Factorial Study to Compare the Safety and Efficacy of Different Combination Antiretroviral Therapy Regimens in Treatment Naive Patients With Advanced HIV Disease and/or CD4+ Cell Counts Less Than 200 Cells/MicroL
Phase of Trial: Phase IV
Latest Information Update: 20 May 2013
At a glance
- Drugs Didanosine (Primary) ; Efavirenz (Primary) ; Lopinavir/ritonavir (Primary) ; Stavudine (Primary) ; Zidovudine (Primary) ; Antiretrovirals; Lamivudine; Lamivudine/stavudine
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms PHIDISA II
- 10 Jun 2017 Biomarkers information updated
- 18 Jun 2011 Results of a subgroup analysis reporting the prevalence of NNRTI drug resistance mutations in patients who achieved viral load <400 copies/mL at 6 months but subsequently had 2 consecutive measures of >1000 copies/mL have been reported in JAIDS.
- 13 Oct 2010 Results were published in the Journal of Infectious Diseases.